|
|
|
 |
 |
|
       |
|
|
|
Licensing Opportunities  Protein Sciences Corporation has the following programs that are available for partnering. Oncology Carcinoembryonic Antigen (CEA) CEA is an antigen commonly found on the surface of breast and colorectal cancer cells. Protein Sciences has created a recombinant vaccine based on this antigen. Phase I studies combining this vaccine with a GM-CSF (Granulocyte Macrophage-Colony Stimulating Factor) adjuvant were completed. This product is covered by a patent owned by Bayer Diagnostics, Tarrytown, NY. For more information on CEA please click here. Thrombospondin-1 Thrombospondin-1 (TSP-1). TSP-1 is a potent inhibitor of angiogenesis and effectively inhibits a wide variety of angiogenic stimuli, including VEGF, proteins that act via tyrosine kinase receptors, G proteins, serine/threonine kinase receptors and lipids. Protein Sciences holds an exclusive worldwide commercial license to an issued patent for the use of TSP-1 for the inhibition of angiogenesis (U.S. 5,192,744 issued March 9, 1993). For more information on TSP-1 please click here. Bio-generics Erythropoietin Erythropoietin (EPO) is a glycoprotein that stimulates red blood cell production that is normally produced in the kidney and the liver. Protein Sciences has cloned, expressed and produced the protein and seeks experienced partners for devising formulation and delivery strategies for rEPO, and for supporting clinical development. For more information on EPO please click here. Infectious Diseases Veterinary Influenza Vaccines Protein Sciences has several subunit vaccine programs ongoing based on recombinant hemagglutinin and neuraminidase proteins produced in BEVS. Partners are sought for the development of the vaccine candidates and to form marketing and distribution agreements. For more information on Veterinary Influenza Vaccines please click here. |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
